ArticleMolecular therapy. Methods & clinical development2020
Circulating miR-4763-3p Is a Novel Potential Biomarker Candidate for Human Adult Fulminant Myocarditis.
Article in Molecular therapy. Methods & clinical development, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 2 syntheses or guidelines pooled it, 33 citations in OpenAlex.
- miRNA Dysregulation in Cardiovascular Diseases: Current Opinion and Future Perspectives.International journal of molecular sciences · 2023Pooled it
- A Systematic Review of miRNA and cfDNA as Potential Biomarkers for Liquid Biopsy in Myocarditis and Inflammatory Dilated Cardiomyopathy.Biomolecules · 2022Pooled it
- MicroRNAs as diagnostic and prognostic biomarkers for viral myocarditis: A systematic review and meta-analysis.International journal of cardiology. Heart & vasculature · 2026Article
- Post-viral myocarditis.Heart failure reviews · 2026Review
- Circulating extracellular microRNAs as tissue-specific biomarkers of human health and disease.Nature communications · 2026Article
- Immune Checkpoint Inhibitor-Associated Myocarditis: Risk, Diagnosis, and Clinical Impact.Journal of clinical medicine · 2026Review
- Endothelial EPAS1 as a prognostic and therapeutic target in acute myocardial infarction: integrative bioinformatics, Mendelian randomization and experimental validation.Frontiers in pharmacology · 2026Article
- Diagnostic efficacy of soluble ST2 in pediatric fulminant myocarditis.Frontiers in pediatrics · 2025Article
- Maximal and sub-maximal exercise tests alter PBMC microRNA expression: insights into sport- and sex-specific variations.Frontiers in physiology · 2025Article
- Emerging Biomarkers in Cardiac Sarcoidosis and Other Inflammatory Cardiomyopathies.Current heart failure reports · 2024Review
- The Role of MicroRNA in the Pathophysiology and Diagnosis of Viral Myocarditis.International journal of molecular sciences · 2024Review
- MiR-4763-3p accelerates lipopolysaccharide-induced cardiomyocyte apoptosis and inflammatory response by targeting IL10RA.Cytotechnology · 2024Article
- Circular RNA as new serum metabolic biomarkers in patients with premature ovarian insufficiency.Archives of gynecology and obstetrics · 2023Article
- Advancing Precision Medicine in Myocarditis: Current Status and Future Perspectives in Endomyocardial Biopsy-Based Diagnostics and Therapeutic Approaches.Journal of clinical medicine · 2023Review
- Wuhan 3 years after the outbreak of the pandemic-cardiological insights and perspectives.Herz · 2023Review
- Idiopathic inflammatory myopathy and non-coding RNA.Frontiers in immunology · 2023Review
- The Role of MicroRNAs in Myocarditis-What Can We Learn from Clinical Trials?International journal of molecular sciences · 2022Review
- The role of non-coding RNAs in myocarditis: a narrative review.Annals of translational medicine · 2022Review
- Soluble ST2 Is a Sensitive and Specific Biomarker for Fulminant Myocarditis.Journal of the American Heart Association · 2022Article
- Identification of lncRNAs and Their Regulatory Relationships with mRNAs in Response toBioMed research international · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Circulating microRNAs (miRNAs) are potential biomarkers in various diseases. However, whether they could serve as biomarkers for human adult fulminant myocarditis (FM) is unknown. Circulating miRNA expression profiles were detected by microarray analysis and validated by quantitative real-time PCR arrays. Meanwhile, Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis was used to determine the critical roles of these circulating miRNAs in FM. Moreover, correlation analysis was employed between miRNAs and the parameters of cardiac functions in FM. Finally, the sensitivity and specificity of circulating long non-coding RNA (lncRNA) expression in FM diagnosis were evaluated using receiver operating characteristic curve analysis. Both microarray and quantitative real-time PCR analysis showed that the expression of miR-4763-3p and miR-4281 were upregulated in the plasma of FM at the onset, and their levels were restored as the clinical symptom recovered. The predicted target genes of miR-4763-3p and miR-4281 are involved in several pathways, mainly inflammatory and cardiac injury response. Moreover, the miRNAs enrichment was negatively correlated with the severity of FM. In addition, the expression levels of circulating miR-4763-3p were unchanged in myocardial infarction (MI) patients but showed high sensitivity and specificity for FM diagnosis. This study provides a global profile of circulating miRNAs in patients with FM, among which miR-4763-3p could serve as a potential biomarker.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.